Scholarlink

Background <p>Non-Hodgkin lymphoma (NHL) are rare diseases that are, therefore, often considered as a&#xa0;disease group. This group usually comprises ICD-10-GM C82–88.</p> Objective <p>In this study potential differences in terms of incidence, age at diagnosis, treatment in a&#xa0;certified center, tumor board presentation, and survival between five different NHL were analyzed.</p> Methods <p>Based on the database of the Cancer Registry of Rhineland-Palatinate in the Institute for Digital Health Data, patients diagnosed with (diffuse) large B‑cell lymphoma (ICD-10-GM C83.3), Waldenström macroglobulinemia (ICD-10-GM 88.0), mantle cell lymphoma (ICD-10-GM C83.1), extranodal marginal zone lymphoma (ICD-10-GM C88.4), or follicular lymphoma (ICD-10-GM C82) in the years 2016–2023 were included. Incidence, age, discussion in a&#xa0;tumor board, treatment in a&#xa0;certified center and event-free survival were analyzed.</p> Results <p>Incidence was quite consistent. The most common age at diagnosis was 70–79&#xa0;years for all analyzed NHL. Event-free survival was favorable for younger patients (<i>p</i> &lt; 0.001). Discussion in a&#xa0;tumor board was reported for only&#xa0;25 to fewer than 5% of NHL. Fewer than 20% of patients were treated in a&#xa0;certified center.</p> Conclusion <p>The incidence of NHL is constant among the different entities. The prognosis of younger patients is better compared to older patients. An increasing number of tumor board conferences might impact survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Einfluss des Alters auf Neuerkrankungen und das eventfreie Überleben bei fünf verschiedenen Non-Hodgkin-Lymphomen

  • 期刊论文

  • 发表日期：

    2025年12月18日

查看全文
  • Benjamin Rieger,
  • Christina Justenhoven

摘要

Background

Non-Hodgkin lymphoma (NHL) are rare diseases that are, therefore, often considered as a disease group. This group usually comprises ICD-10-GM C82–88.

Objective

In this study potential differences in terms of incidence, age at diagnosis, treatment in a certified center, tumor board presentation, and survival between five different NHL were analyzed.

Methods

Based on the database of the Cancer Registry of Rhineland-Palatinate in the Institute for Digital Health Data, patients diagnosed with (diffuse) large B‑cell lymphoma (ICD-10-GM C83.3), Waldenström macroglobulinemia (ICD-10-GM 88.0), mantle cell lymphoma (ICD-10-GM C83.1), extranodal marginal zone lymphoma (ICD-10-GM C88.4), or follicular lymphoma (ICD-10-GM C82) in the years 2016–2023 were included. Incidence, age, discussion in a tumor board, treatment in a certified center and event-free survival were analyzed.

Results

Incidence was quite consistent. The most common age at diagnosis was 70–79 years for all analyzed NHL. Event-free survival was favorable for younger patients (p < 0.001). Discussion in a tumor board was reported for only 25 to fewer than 5% of NHL. Fewer than 20% of patients were treated in a certified center.

Conclusion

The incidence of NHL is constant among the different entities. The prognosis of younger patients is better compared to older patients. An increasing number of tumor board conferences might impact survival.